RxFunction Completes Lineup for walk2Wellness
Long-term Study with Addition of Johns Hopkins Research Site
Johns Hopkins School of Medicine Added to walk2Wellness Study Sites
Eden Prairie, MN – (March 6th, 2020). RxFunction, the medical device company that created Walkasins®, is announcing expansion of its walk2Wellness study to include researchers at Johns Hopkins, with enrollment of its first participants recently completed.
Johns Hopkins School of Medicine is the fifth and final study site added to RxFunction’s walk2Wellness long-term clinical trial (www.clinicaltrials.gov NCT03538756), designed to assess long-term effects of using Walkasins Lower Limb Sensory Neuroprosthesis on peripheral neuropathy patients at high fall-risk. Walkasins is intended to replace nerve function used for detection and signaling of foot pressure sensation. The walk2Wellness trial builds upon the company’s previous published research conducted with Veterans (PLOS ONE) that found short-term in-clinic use of Walkasins immediately improved balance function and gait speed associated with lowered fall-risk among a majority of patients. The other study sites are Minneapolis VA Health Care System, Minneapolis, MN; M Health Fairview, Saint Paul, MN; Baylor College of Medicine, Houston, TX; Marcus Institute for Aging, and Harvard Medical School, Boston, MA.
Mohammad Khoshnoodi, MD, a Board-Certified Neurology specialist is leading the study at the Johns Hopkins site. Dr. Khoshnoodi specializes in neuromuscular disorders in adults including peripheral neuropathies. Dr. Khoshnoodi’s research interests include clinical investigation of treatments for peripheral neuropathies including small fiber neuropathy.
“I am excited that Dr. Khoshnoodi will lead the Johns Hopkins study site” says Lars Oddsson, Ph.D., CTO & Co-Founder of RxFunction. “He heads up a neurology clinic specifically for patients with peripheral neuropathies where he attends to the needs of these patients on a daily basis. Having a study site this closely related to a neurology clinic at a world-class institution is really wonderful for our trial”. Oddsson continues, “The deep clinical experience and expertise Dr. Khoshnoodi brings to the study are highly relevant to the goals of the walk2Wellness trial.”
Walkasins is an external lower limb sensory prosthesis intended to replace the nerve function used for detection and signaling of foot pressure sensation. The company developed Walkasins to help improve balance in patients who experience gait and mobility problems due to sensory peripheral neuropathy, a disorder where the nerves in the feet are damaged causing numbness. Walkasins are available by prescription following evaluation by a trained clinician. According to the National Institutes of Health, an estimated 20 million Americans have some form of peripheral neuropathy, commonly a consequence of diabetes and chemotherapy, and widely present in the elderly population. To learn more about Walkasins, visit www.rxfunction.com.
About RxFunction, Inc.
RxFunction™ is a medical device company with a mission to design and market medical technologies that restore balance, increase mobility, and enhance confidence for patients at risk of falling. Privately held and headquartered in Eden Prairie, Minnesota, RxFunction created the Walkasins® lower limb sensory prosthesis, building upon patented technology developed by co-founder and scientist Lars Oddsson, PhD. Development of Walkasins was supported by Small Business Innovation Research grants from the National Institutes of Health (AG040865) and the product is manufactured in Minnesota.
© 2020 RxFunction, Inc. All Rights Reserved. AP-10067v0 0320. Walkasins® and RxFunction™ are trademarks of RxFunction, Inc.